|Articles|April 21, 2016
FDA's Breakthrough Designation is Working, Says Report
April 21, 2016.
Advertisement
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
The Agentic AI Revolution in Biopharma
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5